MiMedx Group (NASDAQ:MDXG – Get Free Report) and Invivyd (NASDAQ:IVVD – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.
Profitability
This table compares MiMedx Group and Invivyd’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MiMedx Group | 1.76% | 12.09% | 9.22% |
| Invivyd | -183.90% | -59.73% | -48.97% |
Institutional and Insider Ownership
79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 70.4% of Invivyd shares are owned by institutional investors. 2.5% of MiMedx Group shares are owned by company insiders. Comparatively, 12.2% of Invivyd shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MiMedx Group | 1 | 0 | 6 | 0 | 2.71 |
| Invivyd | 1 | 2 | 3 | 0 | 2.33 |
MiMedx Group presently has a consensus price target of $8.57, suggesting a potential upside of 83.31%. Invivyd has a consensus price target of $8.00, suggesting a potential upside of 740.34%. Given Invivyd’s higher probable upside, analysts plainly believe Invivyd is more favorable than MiMedx Group.
Volatility & Risk
MiMedx Group has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500.
Valuation & Earnings
This table compares MiMedx Group and Invivyd”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MiMedx Group | $418.63 million | 1.63 | $48.58 million | $0.04 | 116.90 |
| Invivyd | $53.43 million | 5.25 | -$52.49 million | ($0.33) | -2.88 |
MiMedx Group has higher revenue and earnings than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.
Summary
MiMedx Group beats Invivyd on 11 of the 14 factors compared between the two stocks.
About MiMedx Group
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins. The company’s patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company’s products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.
About Invivyd
Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.
